- Biff F Palmer, MD
Biff F Palmer, MD
- Professor of Internal Medicine
- University of Texas Southwestern Medical Center
- William L Henrich, MD, MACP
William L Henrich, MD, MACP
- Professor of Medicine
- President of the Health Science Center
- University of Texas Health Science Center School of Medicine
Uremic polyneuropathy is common among patients with end-stage renal disease (ESRD) [1-3]. Polyneuropathy generally develops only in patients with significantly reduced glomerular filtration rate (GFR) and is an indication to initiate dialysis. However, patients already being adequately dialyzed may also develop polyneuropathy, although, among such patients, the polyneuropathy is often subclinical and detectable only by electrophysiologic studies.
This topic reviews uremic polyneuropathy. Uremic mononeuropathy, restless leg syndrome, and other neurologic manifestations associated with uremia or dialysis are discussed elsewhere. (See "Uremic mononeuropathy" and "Sleep disorders in end-stage renal disease", section on 'Restless legs syndrome and periodic limb movement disorder'.)
PATHOLOGY AND PATHOGENESIS
Uremic polyneuropathy is a distal, symmetrical, mixed sensorimotor neuropathy that is characterized by demyelination and axonal degeneration . Axonal degeneration appears to be the primary abnormality and results in secondary segmental demyelination. These changes are most severe distally, and longer axons are affected first. In addition to peripheral nerve involvement, demyelination of the posterior columns and other portions of the central nervous system has also been described .
The cause of uremic polyneuropathy is not known . Factors that have been suggested to contribute include deficiencies of thiamine, zinc, and biotin and decreased transketolase activity . Increases in phenols, myoinositol, beta2-microglobulin and other middle molecular weight substances, and hyperparathyroidism have also been suggested to contribute [5-7].
Uremic polyneuropathy is common among dialysis and nondialysis chronic kidney disease (CKD) patients. Among dialysis patients, 60 to 100 percent of patients have electrophysiologic signs of impaired nerve function, although a lower percentage of patients are symptomatic [8-11].
- Raskin NH, Fishman RA. Neurologic disorders in renal failure (first of two parts). N Engl J Med 1976; 294:143.
- Fraser CL, Arieff AI. Nervous system complications in uremia. Ann Intern Med 1988; 109:143.
- Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007; 35:273.
- Guolo M, Stella AM, Melito V, et al. Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Int J Biochem Cell Biol 1996; 28:311.
- Tegnér R, Lindholm B. Uremic polyneuropathy: different effects of hemodialysis and continuous ambulatory peritoneal dialysis. Acta Med Scand 1985; 218:409.
- Lindsay RM, Bolton CF, Clark WF, Linton AL. The effect of alterations of uremic retention products upon platelet and peripheral nerve function. Clin Nephrol 1983; 19:110.
- Bansal VK, Bansal S. Nervous system disorders in dialysis patients. Handb Clin Neurol 2014; 119:395.
- Bolton CF, Young GB. Uremic neuropathy. In: Neurological Complications of Renal Disease, Butterworth (Ed), Boston 1990. p.76.
- Baumgaertel MW, Kraemer M, Berlit P. Neurologic complications of acute and chronic renal disease. Handb Clin Neurol 2014; 119:383.
- Laaksonen S, Metsärinne K, Voipio-Pulkki LM, Falck B. Neurophysiologic parameters and symptoms in chronic renal failure. Muscle Nerve 2002; 25:884.
- Krishnan AV, Phoon RK, Pussell BA, et al. Altered motor nerve excitability in end-stage kidney disease. Brain 2005; 128:2164.
- Aggarwal HK, Sood S, Jain D, et al. Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease. Ren Fail 2013; 35:1323.
- Yosipovitch G, Yarnitsky D, Mermelstein V, et al. Paradoxical heat sensation in uremic polyneuropathy. Muscle Nerve 1995; 18:768.
- Makkar RK, Kochar DK. Somatosensory evoked potentials (SSEPs); sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) in chronic renal failure. Electromyogr Clin Neurophysiol 1994; 34:295.
- Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg 2004; 107:1.
- Ropper AH. Accelerated neuropathy of renal failure. Arch Neurol 1993; 50:536.
- Rodríguez-Iturbe B, García R, Rubio L, et al. Acute glomerulonephritis in the Guillain-Barré-Strohl syndrome. Report of nine cases. Ann Intern Med 1973; 78:391.
- Panjwani M, Truong LD, Eknoyan G. Membranous glomerulonephritis associated with inflammatory demyelinating peripheral neuropathies. Am J Kidney Dis 1996; 27:279.
- Ho DT, Rodig NM, Kim HB, et al. Rapid reversal of uremic neuropathy following renal transplantation in an adolescent. Pediatr Transplant 2012; 16:E296.
- Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280:1831.
- Bazzi C, Pagani C, Sorgato G, et al. Uremic polyneuropathy: a clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients. Clin Nephrol 1991; 35:176.
- Said G. Uremic neuropathy. Handb Clin Neurol 2013; 115:607.